LEADER 01363nam  2200361Ia 450 
001 9910699111803321
005 20230902162255.0
035   $a(CKB)5470000002400782
035   $a(OCoLC)466868919
035   $a(EXLCZ)995470000002400782
100   $a20091118d2009      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $epostmarketing studies and clinical trials, implementation of section 505(o) of the Federal Food, Drug, and Cosmetic Act
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research :$cCenter for Biologics Evaluation and Research,$d[2009]
215   $a1 online resource (13 pages)
300   $a"Draft guidance."
300   $a"Drug safety."
300   $a"July 2009."
517   $aGuidance for industry 
606   $aClinical trials$xGovernment policy$zUnited States
615  0$aClinical trials$xGovernment policy
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699111803321
996   $aGuidance for industry$93434577
997   $aUNINA